Everything you care about in one place

Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.

Get Feeder

ema.europa.eu

What's new

Get the latest updates from What's new directly as they happen.

Follow now 332 followers

Latest posts

Last updated about 11 hours ago

Human medicines European public assessment report (EPAR): Yervoy, ipilimumab, Date of authorisation: 13/07/2011, Revision: 60, Status: Authorised

about 11 hours ago

Human medicines European public assessment report (EPAR): Yervoy, ipilimumab, Date of authorisation...

Outcome of written procedures finalised during the period from 04 March 2026 to 03 June 2026

about 12 hours ago

Outcome of written procedures finalised during the period from 04 March 2026...

Overview of Network Data Steering Group (NDSG) change management activities 2025-2026

about 12 hours ago

Overview of Network Data Steering Group (NDSG) change management activities 2025-2026

Human medicines European public assessment report (EPAR): Dazluma, troriluzole, Status: Application withdrawn

about 12 hours ago

Human medicines European public assessment report (EPAR): Dazluma, troriluzole, Status: Application withdrawn

Breakthrough medical devices: information session, Online, European Medicines Agency, Amsterdam, the Netherlands, from 24 April 2026, 15:00 (CEST) to 24 April 2026, 17:00 (CEST)

about 12 hours ago

Breakthrough medical devices: information session, Online, European Medicines Agency, Amsterdam, the Netherlands...

Human medicines European public assessment report (EPAR): Tecvayli, teclistamab, Date of authorisation: 23/08/2022, Revision: 8, Status: Authorised

about 12 hours ago

Human medicines European public assessment report (EPAR): Tecvayli, teclistamab, Date of authorisation...

Human medicines European public assessment report (EPAR): Privigen, human normal immunoglobulin (IVIg), Date of authorisation: 24/04/2008, Revision: 33, Status: Authorised

about 12 hours ago

Human medicines European public assessment report (EPAR): Privigen, human normal immunoglobulin (IVIg)...

Cookies

about 19 hours ago

Cookies

ICH E22 General considerations for patient preference studies - Scientific guideline

about 16 hours ago

ICH E22 General considerations for patient preference studies - Scientific guideline

Appendix 1: Acceptable intakes established for N-nitrosamines

about 16 hours ago

Appendix 1: Acceptable intakes established for N-nitrosamines

Fee regulation working arrangements

about 18 hours ago

Fee regulation working arrangements

Human medicines European public assessment report (EPAR): Evfraxy, denosumab, Date of authorisation: 30/06/2025, Revision: 2, Status: Authorised

1 day ago

Human medicines European public assessment report (EPAR): Evfraxy, denosumab, Date of authorisation...